A Randomised, Open-Label, Food Effect and Formulation Bioavailability Study of Two Vamifeport Oral Formulations in Healthy Male and Female Adults
Latest Information Update: 19 Aug 2022
Price :
$35 *
At a glance
- Drugs Vamifeport (Primary)
- Indications Beta-thalassaemia; Iron overload; Sickle cell anaemia
- Focus Pharmacokinetics
- Sponsors Vifor
- 11 Jan 2022 Status changed from recruiting to completed.
- 05 Nov 2021 Status changed from not yet recruiting to recruiting.
- 19 Oct 2021 New trial record